Clinical trial
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
NCT07245680
Study timeline
Study start (actual)2026-04-28Date precision: day
Registry last updated2026-05-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Pulmonary Arterial Hypertension (PAH)unresolved
Comorbiditiesunresolved
Cardiovascular Disease (CVD)unresolved
Interventions
TadalafilDRUG · verified · RxNorm: tadalafil
AmbrisentanDRUG · verified · RxNorm: ambrisentan
Sponsors & collaborators
Assistance Publique - Hôpitaux de Parislead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07245680 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.